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Here we report the discovery of tetracyclic benzo-
thiazepines (BTZs) as highly potent and selective
antimalarials along with the identification of the
Plasmodium falciparum cytochrome bc1 complex
as the primary functional target of this novel
compound class. Investigation of the structure
activity relationshipwithin this previously unexplored
chemical scaffold has yielded inhibitors with low
nanomolar activity. A combined approach employing
genetically modified parasites, biochemical profiling,
and resistance selection validated inhibition of cyto-
chrome bc1 activity, an essential component of the
parasite respiratory chain and target of the widely
used antimalarial drug atovaquone, as the mode of
action of this novel compound class. Resistance to
atovaquone is eroding the efficacy of this widely
used antimalarial drug. Intriguingly, BTZ-based
inhibitors retain activity against atovaquone resistant
parasites, suggesting this chemical class may
provide an alternative to atovaquone in combination
therapy.
INTRODUCTION
With an estimated 300–500 million cases and a death toll of
0.8–1.2 million reported in 2008, malaria remains the most
deadly parasitic disease, and it along with HIV/AIDS and tuber-
culosis, comprise the world’s most significant infectious
diseases. (Aregawi et al., 2008) Of the four Plasmodium species1602 Chemistry & Biology 18, 1602–1610, December 23, 2011 ª2011that infect humans, Plasmodium falciparum accounts for most
malaria fatalities, which occur primarily in young children and
pregnant women in sub-Saharan Africa. Parasite resistance to
most of the available falciparum malaria chemotherapies has
compromised efforts to reduce disease mortality and morbidity.
Because most of the currently used drugs are variations on the
molecular templates of their predecessors, new chemotypes
exploiting highly sensitive and established targets in a resis-
tance-orthogonal manner represent a powerful approach for
the development of antimalarial drugs with activity against other-
wise resistant malaria parasites. (Biagini et al., 2008; Winter
et al., 2008; Kelly et al., 2009) In an effort to diversify the current
stock of antimalarial chemotherapeutic agents, we have insti-
tuted a high-throughput screening campaign of small-molecule
libraries for novel, drug-like compounds with whole-cell antima-
larial activity, limited susceptibility to established mechanisms of
drug resistance, and minimal toxicity to mammalian cells, as
a pathway to medicinal chemistry optimization and preclinical
development of lead compounds (Baniecki et al., 2007). We
recently identified over 100 small molecules with submicromolar
activity against both drug sensitive and resistant P. falciparum
strains from an 79,000 compound screening collection
(Baniecki et al., 2007; Martyn et al., 2010a, 2010b; Urgaonkar
et al., 2010; Barker et al., 2011). The majority of these
compounds are structurally unrelated to established antimalar-
ials and may have novel cellular targets or distinct binding
modes, and thus may evade existing resistance mechanisms.
As with any forward chemical genetics screen, the identification
of the molecular target of hit compounds poses one of the
greatest challenges (Stockwell, 2000). In this study, a pathway-
specific whole organism screen was used as secondary assay
to identify those compounds from our hit set with antimalarial
activity that exert their primary activity by inhibiting the parasite
mitochondrial electron transport chain (ETC), a previouslyElsevier Ltd All rights reserved
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Figure 1. Electron Transport Chain of P. falciparum
Enzymes of the ETC are associated with the inner mitochondrial membrane.
Alternative Complex I (pfNDH2) is a nonproton pumping enzyme, therefore the
primary generators of the mitochondrial proton-motive force are Complexes III
and IV. Other components contributing to the respiratory chain include
Complex II (succinate dehydrogenase), and pfDHOD. Exogenous expression
of scDHOD bypasses the electron transport chain through complex III.
In addition, glycerol-3-phosphate dehydrogenase and malate:quinone
oxidoreductase have been identified as mitochondrial dehydrogenases in
P. falciparum that generate reduced CoQ. However, contribution of these
additional dehydrogenases to overall flux seem to be small compared to the
displayed components and are therefore omitted for clarity (Fry and Beesley,
1991).
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Figure 2. Expression of scDHOD Conveys Resistance to Tetracyclic
Benzothiazepines
Wild-type Dd2 (black triangles) and Dd2-scDHOD (open triangles) parasite
strains were grown in the presence of varying drug concentration for 48 hr.
Growth was assessed by (3H)-hypoxanthine incorporation.
(A) Structures of BTZ compounds 1 and 2 identified in the small molecule
screen.
(B) Dose-effect curves for BTZ 1 and Dd2-scDHOD parasite strains. Growth in
the absence of drug was set at 100%. Data represent mean values ± standard
deviation of triplicate experiments at each condition.
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et al., 1993; Srivastava et al., 1997).
Painter et al. (2007) reported that the mitochondrial ETC in the
erythrocytic stage of the malaria parasite functions solely to
regenerate ubiquinone as the cofactor for the mitochondrial
membrane-associated type II dihydroorotate dehydrogenase
(DHOD) in the de novo pyrimidine biosynthetic pathway. The
erythrocytic parasite proliferates in human red blood cells, and
in that environment relies completely on de novo pyrimidine
biosynthesis. The resulting ubiquinone dependency and, in
turn, need for complexes I–III of the ETC, can be circumvented
in recombinant parasites by the expression of a type I DHOD
from Saccharomyces cerevisiae (scDHOD), a cytosolic form of
the enzyme, which uses fumarate or NAD as an electron
acceptor in lieu of ubiquinone (Painter et al., 2007). Compounds
that target complexes I–III of the ETC or pfDHOD as their primary
mode of action exhibit reduced activity against the transgenic
scDHOD-expressing parasite strain compared to the wild-type
P. falciparum strain (Figure 1).
Here we describe a novel antimalarial drug template identified
by the high-throughput screening campaign, its chemical opti-
mization and basic structure-activity relationship (SAR) explora-
tion, and the identification of its ETCmolecular target by a combi-
nation of a pathway-specific transgenic whole-cell screens,
traditional in vitro enzyme assays, and finally by the generation
and genetic mapping of compound-specific parasite resistance.
In addition to the specific molecules reported, this approachChemistry & Biology 18, 1602–161highlights the importance of genetic mapping in developing
drugs for neglected diseases.RESULTS
Tetracyclic Benzothiazepines Are a Novel Class
of Potent Inhibitors of the P. falciparum Electron
Transport Chain
To identify novel antimalarials that act through inhibition of the
P. falciparum ETC, we profiled compounds identified in the
primary screen for differential growth inhibition of a wild-type
strain and a scDHOD-expressing transgenic strain with an iden-
tical genetic background. Out of all compounds tested, two
molecules (1 and 2, Figure 2A) with a common tetracyclic benzo-
thiazepine (BTZ) molecular scaffold were identified as having
significantly reduced activity against the transgenic scDHOD-
expressing Dd2 strain with respect to the parental Dd2 strain
suggesting that the BTZs target enzymes in the mitochondrial
ETC (Figure 2B).
The tetracyclic BTZ scaffold is an unexplored compound class
with no reports on its biological activity. To explore the SAR and
to identify analogs with increased potency, a focused library of
BTZ derivatives was synthesized using a newly developed
two-step procedure based on a proline catalyzed Knoevenagel
condensation followed by a Lewis acid promoted Michael
addition/intramolecular imine formation sequence (Figure 3)
(Krysin et al., 2003; Ramachary et al., 2004). This effort identified
compound 3 as a potent inhibitor of parasite growth with
chloroquine-like potency against wild-type 3D7 strain (IC50 =
16 nM), and more importantly, activity against the multidrug-
resistant Dd2 strain (IC50 = 16 nM). Compound 3 is 25-fold
less active compared to the clinically optimized activity of atova-
quone (IC50 = 0.7 nM). A clear SAR trend emerged from the
synthesized analogs.We found that the R2 site waswell tolerated
by small hydrophobic substituents like methoxy and methyl. The
importance of nonpolar aliphatic groups at R1 for enhanced0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1603
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decreased the potency.
We next profiled a selected set of 11 BTZ analogs (1–11)
against the scDHOD-expressing transgenic strain to assess
differential activity compared to the parental Dd2 strain (Baniecki
et al., 2007). The rescue phenotype in the presence of scDHOD
expression was associated with compounds 1–9, whereas no
significant change in viability was noted for 10 and 11 (Table 1).
Cytochrome bc1 Is the Primary Target of BTZs
The principal mode of action for the compounds with differential
activity was expected to fall within the bypassed region of the
ETC comprising complexes I, II, and III, and pfDHOD (Figure 1).
To further narrow down the list of possible targets of BTZs
1–11, we profiled these compounds in uncoupled biochemical
assays. In vitro assays for three of the four P. falciparum ETC
components (complex I, complex III, andpfDHOD)hadpreviously
been established in our labs (Patel et al., 2008; Dong et al., 2009).
Complex I is an alternative NADH dehydrogenase (pfNDH2) that
catalyzes the transfer of electrons from NADH to ubiquinone
(CoQ) (Kerscher, 2000). pfDHOD catalyzes the oxidation of
L-dihydroorotate (L-DHO) to orotate using a flavin mononucleo-
tide (FMN) cofactor that is re-oxidized by CoQ (Jones, 1980).
None of the evaluated BTZs were found to inhibit either recom-
binant pfNDH2 or pfDHOD activity at concentrations up to
20 mM (Table 1). Remarkably, however, the BTZ analogs were
found to be potent inhibitors of complex III (cytochrome bc1) in
a manner that correlated well with the EC50 values determined
for parasite growth (Table 1). In contrast, human cytochrome
bc1 was relatively insensitive to BTZ treatment, indicating that
some members of the BTZ family possess high species selec-
tivity. It should be noted that all compounds with nanomolar
activity were 100- to >1,250-fold more active against pfCYT
bc1compared tohsCYTbc1, a selectivitywindow that is generally
considered appropriate for drug development, and some were
even comparable to the selectivity of atovaquone (1,750-fold).
Cytochrome bc1 is a homodimeric, multisubunit mitochondrial
inner membrane enzyme complex that transfers electrons from
ubiquinol to cytochrome c. It is comprised of a cytochrome
b subunit (CYT b), a Rieske iron-sulfur protein, and a cytochrome
c1 subunit (Trumpower, 1990). Inhibition of electron transfer
through the cytochrome bc1 complex is linked to proton translo-
cation via the proton motive Q cycle, in which ubiquinol is
oxidized at one site (Qo or Center P), and then re-reduced at
another site (Qi or Center N) (Hunte et al., 2003). Known inhibitors
of the cytochrome bc1 complex have been proposed to act
mainly as ubiquinol/ubiquinone antagonists by interfering with
the ubiquinol oxidation or ubiquinone reduction steps of the
proton-motive Q cycle (Trumpower andGennis, 1994). A number1604 Chemistry & Biology 18, 1602–1610, December 23, 2011 ª2011of mutants resistant to inhibitors of the cytochrome bc1 complex
carrymutations in the ubiquinol or ubiquinone binding sites of the
CYT b gene (Brasseur et al., 1996).
BTZs Bind to the Quinol-Binding Site in a Mode Distinct
from Atovaquone
Cytochrome bc1 is the validated target of atovaquone (ATV),
a potent inhibitor of both proliferating erythrocytic stage and
sexual stage parasites, used in synergistic combination with pro-
guanil, and marketed under the trade name Malarone (Fry and
Pudney, 1992; Fleck et al., 1996; Srivastava et al., 1997; Chulay,
1998; Korsinczky et al., 2000). ATV resistance is associated with
single nucleotide polymorphisms in the Qo and Qi sites in the
CYT b gene (Srivastava et al., 1999; Kessl et al., 2007). In order
to validate cytochrome bc1 as a BTZ target and to assess the
molecular basis for biological activity of BTZ, we generated
resistant P. falciparum parasites using 1 as the selecting agent
at 103 IC50 concentration. Starting with 2 3 10
9 parasites
(Dd2), we were able to isolate a parasite clone (Dd2-BTZ1) after
90 days of continuous culturing that was5-fold less sensitive to
1. Continuous selection with adjusted drug concentrations for
additional 60 days resulted in the generation of a second strain
with 80-fold resistance (Dd2-BTZ2). Importantly, the BTZ resis-
tant clones were also resistant to other BTZs but retained sensi-
tivity to ATV. For comparison, previous efforts by Rathod et al.
(1997) to select for ATV resistant parasite strains, starting at
105–106 parasites (W2 and 3D7), yielded resistant isolates after
a 2-month selection period. However, the authors also demon-
strated that resistance selection depends on both parasite strain
and selection agent, making direct comparisons difficult (Rathod
et al., 1997).
The CYT b gene was PCR amplified and sequenced from the
BTZ-resistant mutant lines. A single point mutation, G391A, re-
sulting in amino acid change, G131S, was identified in Dd2-
BTZ1. The G131S mutation lies within the quinol binding site
Qo (i.e., site of ubiquinol oxidation) binding regions of CYT b (Fig-
ure 4). Interestingly, Dd2-BTZ2 contained an additional point
mutation to the one described above. The second point muta-
tion, T791A, translating to a F264L amino acid change, is located
distal to the first mutation in the predicted ubiquinol-binding
region (Figure 4). These results are in accord with observations
that ATV-resistance associated point mutations in the same
region also accumulate with extended drug pressure.
BTZs Are Highly Synergistic with Proguanil and Exhibit
Minimal Propensity to Cross-Resistance with
Atovaquone
To determine potential cross-resistance between the BTZs and
ATV we profiled two established ATV-resistant P. falciparumElsevier Ltd All rights reserved
Table 1. Inhibition of In Vitro Enzyme Activity and In Vivo Parasite Proliferation by BTZs
Compound R2 R1
EC50 Growth (mM) IC50 Enzyme Activity (mM)
3D7 Dd2 Dd2-scDHOD pfNDH2 pfDHOD pfCYT bc1 hsCYT bc1
1 H 3-Thiophenyl 0.044 0.157 >5 >20 >20 0.004 ± 0.0014 >5
2 H 4-Fluorophenyl 0.033 0.013 >5 n.a. n.a. 0.014 ± 0.0039 >5
3 OMe Cyclopropyl 0.016 0.016 >5 >20 >20 0.003 ± 0.0007 0.833 ± 0.201
4 H Cyclopropyl 0.048 0.02 >5 >20 >20 0.007 ± 0.0022 1.090 ± 0.093
5 H Cyclohexyl 0.034 0.022 >5 >20 >20 0.005 ± 0.0016 >5
6 Me 3-Thiophenyl 0.031 0.039 >5 >20 >20 0.011 ± 0.0033 >5
7 H 4-Methoxyphenyl 2 1.12 >5 >20 >20 0.020 ± 0.0025 >5
8 H 4-Cyanophenyl 0.79 0.27 >5 >20 >20 0.049 ± 0.0068 >5
9 H 4-(3-Dimethylamino)
propoxyphenyl
1.47 0.57 >5 >20 >20 1.082 ± 0.084 >5
10 H 2-Methoxyphenyl >5 >5 >5 >20 >20 1.335 ± 0.366 >5
11 H 3,4-Dihydroxyphenyl >5 >5 >5 >20 >20 >5 >5
Atovaquone 0.001 0.001 >5 >20 >20 0.0002 ± 0.00003 0.350 ± 0.012
Reported EC50 values for Dd2 and Dd2-scDHOD parasite strains are based on dose-effect curves. IC50 calculations for enzyme activity were deter-
mined by best-fit Michaelis-Menten kinetic curves. Cytochrome bc1 enzyme activity was determined using purifiedmitochondrial fractions. BTZs, ben-
zothiazepines; n.a., not available.
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CYT b mutations, M133I and G280D, and TM90C6B, bearing
the mutation, Y268S, the most prevalent polymorphism confer-
ring clinical failure of ATV (Korsinczky et al., 2000). Relative
to the ATV-sensitive Dd2 line, FCR3 and TM90C6B showed
1- and 4-fold resistance to 1, respectively. In contrast, ATV
was >1,000-fold less effective in the two mutant lines. In addi-
tion, 2 demonstrated similar efficacy. These results indicate
that the antimalarial activity of the BTZs is only modestly
compromised in P. falciparum mutants conferring high-level
ATV resistance, suggesting that the BTZs may inhibit cyto-
chrome bc1 activity in a different manner than ATV.
To further characterize the role of BTZ and cytochrome bc1,
wild-type parasites were cotreated with both 1 and proguanil
(PG), a drug that does not independently affect electron trans-
port but has been shown to synergistically enhance the ability
of ATV to collapse the membrane potential (Canfield et al.,
1995; Srivastava et al., 1999). Indeed, in two culture-adapted
lines, Dd2 and D10, 1 demonstrated a synergistic interaction
with PG, providing further evidence that the BTZs act on cyto-
chrome bc1 by a mode of action comparable to atovaquone
(Table 2; Figure S1 available online). As previously reported,
combination treatment with PG was unexpectedly able to
restore sensitivity of the scDHOD-expressing strain to ATV. We
tested the BTZ compounds in combination with PG and likewise
observed restored sensitivity in the transgenic strain (Painter
et al., 2007). Interestingly, the scDHOD-transgenic strain syner-
gized more potently with PG and was hypersensitive to BTZ
compared to the wild-type strain even at low concentrations
(>0.5 mM) of PG.
BTZ Liver Stage Activity and In Vivo Profiling
Atovaquone is only one of the few known antimalarials that
are active against both blood and liver stage parasites
(IC50 = 0.3 nM). To confirm comparable characteristics of
the BTZs, we profiled two representative analogs, 1 and 2, in aChemistry & Biology 18, 1602–161Plasmodium berghei liver stage assay in mammalian Hep2G
cells. Although Hep2G cells were not sensitive to either
compound, both compounds inhibited liver stage P. berghei at
IC50 = 151 ± 42 nM and 391 ± 28 nM, respectively.
To assess the in vivo activity of the BTZs, we profiled
compounds 1 and 2 in a murine model system. We first estab-
lished a tolerated dose of these BTZs. Compounds were admin-
istered by intraperitoneal (i.p.) injection at two concentrations
(50 mg/kg and 100 mg/kg) to uninfected mice two times a day
(b.i.d.). Treatment with BTZ 1 resulted in some lethargy for 1 hr
following dosing whereas BTZ 2 was tolerated well without any
clinical signs of toxicity. LC/MS/MS analysis of the plasma
samples established moderate exposure at approximately three
to five times blood stage IC50 concentrations (Figure S2). We
performed a follow-up study exploring the in vivo activity of 1
and 2 against P. berghei according to an acute malaria model
adapted from Peters’ ‘‘4-day suppressive test’’ (Barker et al.,
2011). Although the compounds were well tolerated at the high-
est concentrations, indicating an absence of acute toxicity, we
did not observe a significant decrease in peripheral blood para-
sitemia (Figure S3). We speculate that these results are a reflec-
tion of the short half-life of the tested compounds leading to
insufficient exposure (see Supplemental Information), and
possibly decreased activity against blood stage P. berghei
compared to P. falciparum. Future medicinal chemistry efforts
will be required to identify analogs with improved in vivo DMPK
parameters.
DISCUSSION
The synergistic combination of ATV and proguanil (PG) repre-
sents one of the most useful antimalarial medications (Malarone,
GlaxoSmithKline). Unfortunately, P. falciparum quickly develops
resistance to ATV compared to other antimalarial drugs. When
administered as a single treatment therapy during clinical trials,
ATV resistance is observed within 28 days, spurring the search0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1605
Figure 4. Mapping of BTZ Resistance Mutations on Saccharomyces
cerevisiae Cytochrome bc1 Crystal Structure
BTZ resistance mutations (red) and ATV resistance mutations (green) are
mapped on the crystal structure coordinates of S. cerevisiae cytochrome bc1
(PDB code: 1EZV). cytochrome c1 (yellow), cytochrome b (blue), and heme
(orange). For homology alignment see Figure S4.
Table 2. Inhibition of In Vivo Parasite Proliferation by 1 and 2 in
Combination with Proguanil
Compound
Proguanil
(nM)
Dd2
(nM)
Dd2-scDHOD
(nM)
Fold
Resistance
1 0.05 370 6015 16.3
1 0.5 81 78 0.96
1 5 29 7.9 0.27
2 0.05 388 2978 7.7
2 0.5 108 51 0.47
2 5 39 3.8 0.1
EC50 values for Dd2 and Dd2-scDHOD parasite strains are based on
dose-effect curves. See also Figures S1, S2, and S3.
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PG (Looareesuwan et al., 1996). Even when used in combination
with PG, which potentiates the activity of ATV, spontaneous
resistance, mostly attributed to a mutation of Y268 in CYT b is
observed clinically, which has spurred the discovery of alternate
inhibitors of Plasmodium cytochrome bc1 complex (Schwo¨bel
et al., 2003). Once ATV resistance has been established, the
potency of the combination with PG is significantly reduced
and can lead to treatment failure (Fivelman et al., 2002). Acridine-
diones have been characterized as selectively potent inhibitors
of parasite cytochrome bc1 (Biagini et al., 2008). Quinolone
derivatives, and a series of pyridones related to the anticoccidial
drug, clopidol, have also been implicated as cytochrome bc1
inhibitors (Winter et al., 2008). Although these molecules show
promise, the ability of themalaria parasite to generate resistance
necessitates the continued development of novel electron trans-
port chain inhibitors, ideally with distinct inhibitory modes that
are less likely to cause high level resistance as a result of a single
point mutation.
Here we have used a combination of forward chemical
genetics, pathway-based screens, and Plasmodium genetics
to identify tetracyclic BTZs as a novel class of highly potent
anti-malarial compounds that are active against both blood
and liver stage, and provided evidence that these compounds
likely act via inhibition of P. falciparum cytochrome bc1 activity.
In addition, we demonstrate that BTZs exhibit synergy with PG
comparable to that of ATV. The underlying basis for this synergy
is not yet fully understood. It has been speculated that the
primary mode of action of ATV is the depolarization of the mito-
chondrial membrane (Biagini et al., 2006). Interestingly, we1606 Chemistry & Biology 18, 1602–1610, December 23, 2011 ª2011observed that low-dose combination treatment with PG renders
scDHOD expressing transgenic parasites hypersensitive to
BTZs. Similar findings have been recently reported for ATV
(Painter et al., 2007). This observation suggests that disruption
of pyrimidine biosynthesis through indirect inhibition of DHOD,
at least in combination with PG, is not the sole basis for the
antimalarial activity of BTZs (and ATV). BTZs thus provide an
orthogonal set of tool compounds that may enable a better
understanding of the enigmatic nature of the synergistic relation-
ship of PG and cytochrome bc1 inhibitors.
Based on drug selection analysis, we defined two mutations
in CYT b, G131S and F264L, both within the predicted ubiquinol
binding site, that convey resistance to BTZ treatment. The mito-
chondrial DNA inmalaria parasites is remarkably well conserved,
and little sequence variation is observed within the parasite
species even from geographically isolated clones (McIntosh
et al., 1998). Therefore, rapid sequence changes, not unlike
those observed in ATV-resistant parasites, indicates a selective
advantage for these mutations in the presence of BTZ. Interest-
ingly, minimal cross-resistance for the BTZs with an ATV-resis-
tant strain indicates that whereas these molecules likely target
the same enzyme, the binding sites are spatially distinct.
Although ATV is a well-studied inhibitor of cytochrome bc1, the
identification of additional inhibitors of this enzyme that do not
exhibit cross-resistance with ATV-resistant parasite strains
suggests that the mitochondrial ETC can still be profitably ex-
ploited as a drug target.
Based upon homologous experiments in yeast, it has been
suggested that residue alterations in the CYT b protein may
lead to a loss of respiratory fitness in P. falciparum (Wenz
et al., 2007; Fisher and Meunier, 2008). Novel inhibitors with
differential binding capacities for cytochrome bc1 used in combi-
nation with ATV might therefore restrict the emergence of drug
resistance (Srivastava et al., 1999). In addition, evaluation of
novel cytochrome bc1 inhibitors such as the BTZs against
diseases for which ATV is used as a prophylactic or acute treat-
ment, such as toxoplasmosis and Pneumocystis pneumonia
(PCP), may lead to additional chemotherapeutic applications
(Petersen, 2007; Kazanjian et al., 2001; Rosenberg et al., 2001;
Kessl et al., 2007). Although medicinal chemistry optimization
for improved exposure will be required to achieve in vivo effi-
cacy, the BTZs appear to be well tolerated in vivo, suggesting
a promising future lead for the development of cytochrome bc1
targeted antimalarials.Elsevier Ltd All rights reserved
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TheWorldHealthOrganizationestimates that300–500million
people each year are infected with malaria. For approxi-
mately 800,000 patients—mostly young children and preg-
nant women in sub-Saharan Africa—the disease is fatal,
while many more suffer from permanent disabilities. To
counter these grim statistics, new drugs that are refractory
to existing resistance mechanisms are urgently needed.
Here,we report thediscoveryof tetracyclicbenzothiazepines
(BTZs) as highly potent and selective antimalarials. Through
an integrated chemogenomic approach combining forward
chemical genetics, pathway-based screening, biochemical
profiling, and Plasmodium genetics, we have identified the
Plasmodium falciparum cytochrome bc1 complex as the
primary functional targetof this novel compoundclass.Cyto-
chrome bc1 is also the target of atovaquone (ATV), one of the
mainstay drugs used to treat malaria. Unfortunately, resis-
tance to ATV is eroding the efficacy of this widely used
antimalarial drug. Intriguingly, BTZ-based inhibitors retain
activity against ATV-resistant parasites, suggesting this
chemical classmayprovideanalternative toATV in combina-
tion therapy.
EXPERIMENTAL PROCEDURES
Secondary Screening Approach
A total of 108 small molecules previously identified by Baniecki et al. (2007) as
highly active against multidrug-resistant parasites were screened against
a Dd2 transgenic parasite line expressing chromosomally integrated yeast
DHOD (scDHOD). A transgenic P. falciparum strain expressing scDHOD was
generated by amplification of full-length scDHOD from S. cerevisiae genomic
DNA and subsequent cloning into the pLN-ENR-GFP plasmid as a AvrII/XhoI
insert. This pLN-scDHOD plasmid was cotransfected into the Dd2-attB para-
site strain with the Bxb1 integrase expression vector pINT as described by
Nkrumah et al. (2006), and maintained in vitro by method of Trager and Jensen
(1976). Compounds were screened at two fixed concentrations (2.5 and
5 mM), and inhibition of P. falciparum growth was assessed by the relative
reduction of {3H}-hypoxanthine uptake (Geary et al., 1983; Chulay et al.,
1983). IC50 values were determined for compounds showing differential
growth between Dd2 and Dd2-scDHOD lines of P. falciparum relative to
drug-free control cultures. The susceptibility of parasite strains was also deter-
mined for ATV (USP, Rockville, MD), and chloroquine (Sigma-Aldrich).
Synergy experiments were performed in similar fashion. Briefly, BTZ
compounds were serially diluted in 5-fold dilutions in quadruplicate in
96-well assay plates in low hypoxanthine RPMI. Synchronous ring stage
cultures were plated at 0.75% parasitemia in 2% HC in the 96-well plates in
the presence of the indicated concentrations of proguanil. Parasites were
grown for 48 hr and re-invasion was monitored in control wells without drug.
Following addition of 0.75 uCi {3H}-hypoxanthine per well parasites were
grown for additional 24 hr and were harvested. {3H}-hypoxanthine incorpora-
tion was measured by scintillation counting.
IC50 values against 3D7 and Dd2 were determined as reported previously
(Geary et al., 1983).
Activity Assays
For pfNDH2 kinetics experiments, the enzymatic activity of purified His-tagged
pfNDH2 wasmeasured by fluorescence using an assay adapted from Putt and
Hergenrother (2004) (Dong et al., 2009). Thirty microliters of sample solution in
assay buffer (50 mM Tris [8.0], 150 mM KCL, 0.1% Triton) was added in tripli-
cate to wells of a 96-well black plate. Following incubation at 25C for 1 hr,
12 ml of aqueous 2M KOH solution and 12 ml of a 20% acetophenone (in EtOH)
solution were added to each well. The plate was incubated at 4C for 10 min,
followed by addition of 46 ml formic acid, resulting in a final concentration ofChemistry & Biology 18, 1602–161240 mM KOH, 2.4% acetophenone, and 46% formic acid. Plates were then
incubated in an oven at 100C for 15 min. The plate was allowed to cool and
fluorescence was measured on a FlexStation III machine (Molecular Devices)
at 360/444 ex/em (Scheme S1). Thirty microliters of 1 mM to 100 mM NAD+
solution in assay buffer was added in triplicate to wells in order to determine
calibration curves for all kinetics experiments.
For DHOD kinetics experiments, the chromogen reduction assay adapted
for 384-well format as described by Patel et al. (2008) was utilized (Scheme
S2). The assay was performed in a final volume of 60 ml of 100 mM HEPES
(pH 8.0), 150 mM NaCl, 5% glycerol, 0.05% Triton X-100, 500 mM L-DHO,
115 mM Q0, 50 mM 2,6-dichlorophenol-indophenol (DCIP). Compounds
were plated in serial dilution, and the reaction was initiated by addition of
pfDHOD (2 mg/ml final concentration.) The reaction proceeded at 25C for
10 min after which, A600 was measured using an automatic plate reader.
For cytochrome bc1 experiments, mitochondria were isolated as follows:
parasitized erythrocytes were harvested by centrifugation and lysed with
0.05% (w/v) saponin in RPMI. Then parasites were washed three times with
H-medium (0.07 M sucrose, 0.21 M mannitol, 1 mM EGTA, 5 mM MgCl2,
5 mM KH2PO4, and 4 mM HEPES, pH 7.4) and resuspended in the same
medium in the presence of 1 mM PMSF and protease inhibitor cocktail (Roche
Complete). Parasites were disrupted by N2 cavitation (4639 Cell disruption
Bomb, Parr Instrument, Moline, IL, USA) at 1600 psi for 25 min at 4C.
Unbroken cells and cell debris were removed by centrifugation at 1,200 3 g
for 10 min at 4C. The mitochondrial fraction was pelleted at 10,000 3 g for
20 min at 4C. The mitochondrial pellet was gently resuspended in 0.8 M
sucrose, 1 mM EDTA, 10 mM Tris-HCl pH 7.4, and 0.1% BSA prior to separa-
tion on a 1–2 M sucrose gradient. The sample was centrifuged on a gradient at
80,0003 g for 2 hr at 4C. The mitochondria were then recovered and washed
with 1 mM EDTA, 10 mM Tris-HCL pH 7.4 to remove sucrose, and resus-
pended in H-medium with protease inhibitor cocktail and 1 mM PMSF.
Samples were stored at –80C until use. In the case of human mitochondria,
HEK293 human cell line was used as starting material. Cells were pelleted at
400 3 g 10 min and disrupted by N2 cavitation. Mitochondria then were iso-
lated using the method described above. Cytochrome c reductase activity
was assayed by a modification of the method of Fry and Pudney (1992). Mito-
chondria (40 ug/ml) were diluted in reaction buffer (250 mM sucrose, 50 mM
KH2PO4, 0.2 mMEDTA, 1mMNaN3, and 2.5mMKCN) containing 50 uM cyto-
chrome c. Reactions were started by addition of 25 uM decylubiquinol and
monitored by reduction of cytochrome c at 550 nm. To assure the linearity
of the enzymatic reaction only data from the first 60 s were collected. Decylu-
biquinol substrate was prepared by reducing decylubiquinone (Sigma-Aldrich,
St. Louis, MO, USA) in ethanol with sodium borohydride. Decylubiquinol was
aliquoted and stored in acidified ethanol at 80C. Dose-response titration
curves for P. falciparum cytochrome bc1 assays are provided in the Supple-
mental Information (Figure S5).
Strain Handling
The TM90C6B (MRA205) P. falciparum parasite strain, isolated from a Thai
patient who experienced a recrudescence of parasitemia after treatment
with ATV (1,000 mg once a day for 3 days) and pyrimethamine, was tested
for susceptibility to the BTZ compounds (Malaria Research and Reference
Reagent Resource Center) (Fisher andMeunier, 2008). Stepwise in vitro selec-
tion of BTZ-resistant parasite lines was carried out as follows. P. falciparum
Dd2 parasites were initially cultured in one flask and then split into four
25-ml cultures at 5% parasitemia and 5% hematocrit (2 3 109 parasites).
Cultures were expanded to 200 ml flasks and grown in medium containing
the 1 analog at a concentration 10-fold above the IC50. Three days after the first
dosing, each flask was split. One set of four flasks was subjected to contin-
uous drug pressure, whereas the other set of four flasks was treated at
the same concentration intermittently, allowing for the reestablishment of
2%–5% parasitemia between drug treatments. Cultures were dosed until no
viable parasites were microscopically observed. All flasks were maintained
as independent selections. After 90 days two flasks from the original contin-
uous and intermittent splits, BTZ-1 and BTZ-1b, showed evidence of drug
resistance, which was confirmed by growth-inhibition assays. Following
DNA sequencing of the pfCYTb ORF, the BTZ-1 and BTZ-5 strains were
subjected to increasing intermittent drug pressure. After 60 days, BTZ-2 and
BTZ-2b lines were established, showing persistent growth >150 nM 1.0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1607
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The assay was conducted using a luciferase-expressing sporozoite strain of
P. berghei ANKA according to a previously published procedure (Ploemen
et al., 2009). Briefly, 4,000 sporozoites harvested from mosquito salivary
glands were used to infect 12,000 HepG2 cells (ATCC) in the presence and
absence of compounds. The final concentration of DMSO was 0.3%. Parasite
growth was determined 45 hr postinfection with ONE-Glo (Promega) accord-
ing to the manufacturer’s instructions. Addition of BTZ post sporozoite infec-
tion resulted in similar activity. Data analysis was carried out using GraphPad
Prism and all statistic results are given as mean ± standard deviation. The
experiments were repeated two to three times to ensure reproducibility.
DNA Analysis
Parasite DNA was extracted from Dd2 parent and BTZ-5 strains using stan-
dard procedures (Cheng et al., 1997). The CYT b gene was amplified by
PCR (50-ATGAACTTTTACTCTATTAATTTAG-30; 50-TTATATGTTTGCTTGGGA
GCTGTAA-30). PCR was performed using 0.2 mM of each deoxynucleoside
triphosphate, 50 pmol of each primer, and 1.25 U Invitrogen Platinum Taq
(Invitrogen). The mixture was heated to 94C for 2 min and then cycled at
94C for 1 min, 55C for 1 min, and 62C for 3 min over 30 cycles. PCR prod-
ucts were then purified using the PCR Cleanup kit (QIAGEN) and sequenced
using primers described by Korsinczky et al. (2000), cytb1 (50-CTCTATTAATT
TAGTTAAAGCACAC-30), cytb2 (50-ACAGAATAATCTCTAGCACC-30), cytb3
(50-AGCAGTAATTTGGATATGTGGAGG-30 ), and cytb4 (50-ATTTTTAATGCTG
TATCATACCCT-30).
Tolerability Study
The studies were performed at Genzyme following standard protocols. Proto-
cols were Institutional Animal Care and Use Committee-approved, and
animals were housed in Association for Assessment and Accreditation of
Laboratory Animal Care-accredited facilities. Briefly, compounds (formulated
in 15% DMSO, 25% polyvinyl pyrrolidone, and 5% Tween 80 in water at 5
and 10 mg/ml, respectively) were administered i.p. b.i.d. to groups of three
mice (CD-1, female), 5 weeks at 50 mg/kg and 100 mg/kg, respectively. Clin-
ical observationswere recorded at 15-min intervals for 1 hr after administration
of test articles, then hourly for up to 4 hr daily for signs of acute systemic
toxicity. EDTA plasma samples collected from groups 2 and 3 at the following
time points were submitted for exposure analysis at 1 hr, 1 hr (second dose),
and 18 hr.
Liquid Chromatography Tandem Mass Spectrometry
Measurements of plasma exposures of BTZs were carried out using a 4000
QTRAP triple quadrupole mass spectrometer (AB SCIEX, Foster City, CA,
USA) that was coupled to an Agilent 1100 HPLC pump (Agilent Technologies,
Santa Clara, CA, USA) and an HTS PAL autosampler (Leap Technologies,
Carrboro, NC, USA). Plasma samples were extracted (20 ml) using 80 ml of
75/25 acetonitrile/methanol solution containing 0.2 ng/ml valine-d8 internal
standard and 10 ml of each supernatant were analyzed. Chromatographic
separations were achieved using a 100 3 3 mm Atlantis T3 column (Waters,
Milford, MA, USA) that was initially eluted isocratically at 300 ul/min with
95% mobile phase A (0.1% formic acid in water) and 5% mobile phase B
(0.1% formic acid in acetonitrile) for 3 min, followed by a 5 min linear gradient
to 100%mobile phase B. Multiple reaction monitoring (MRM) transitions were
monitored in the positive ion mode using a 100 ms dwell time and collision
energy setting of 30. Electrospray ionization source settings were: curtain
gas, 20; source potential, 5 kV; source temperature, 400C; gas1, 30; gas2,
35; and declustering potential, 40. Calibration curves were generated by anal-
ysis of serially diluted reference solutions. MultiQuant software (Version 1.1;
AB SCIEX) was used for peak integration and data were manually reviewed
for quality of integration.
P. berghei In Vivo Assay
The acute P. berghei rodent model is adapted from the 4-day suppressive test
(Peters, 1987). The acute portion of the protocol is identical to that recommen-
ded byMMV-ESAC (Fidock et al., 2004). Animals were maintained and housed
according to National Institutes of Health guidelines and were allowed to accli-
matize for 1 week prior to study. This protocol has been approved by the Insti-
tutional Animal Care and Use Committee of the University of Puerto Rico.1608 Chemistry & Biology 18, 1602–1610, December 23, 2011 ª2011On Day 0, groups of five mice are infected by tail vein injection with 0.2 ml
heparinized blood diluted to contain 2 3 107 parasites per dose. Compound
stocks were prepared in 15% DMSO, 25% polyvinyl pyrrolidone, and 5%
Tween 80 in water. Animals were dosed 100 ml/dose (adjusted for animal
weight), once a day (q.d.) on Day 0; b.i.d. i.p. on Day 1–Day 3 (Day 0 = first
day of study); animals in the Control-group received vehicle alone. On Day 4
(fifth day of assay) blood was collected by tail-nick; thin smear microscope
slides were prepared (three slides/animal) and stained using Diff Quick. Para-
sitized erythrocytes were counted and compared with the total number of
erythrocytes per microscopic field to determine the percent parasitemia. A
minimum of 450 erythrocytes was counted. In some cases with very low para-
sitemia data were originally captured as ‘‘at least xx parasitemia.’’ These were
later converted to percent parasitemia by dividing by 450 (the minimum
number erythrocytes counted) and multiplying by 100. Animals were eutha-
nized at the end of the study.
General Procedure for the Synthesis of Benzothiazepines
To a glass vial equipped with a magnetic stirring bar was added 1mmol of 1,3-
indandione, 1 mmol of aldehyde, 0.2 mmol of the catalyst L-Proline, and then
MeOH (2 ml). The reaction mixture was stirred at room temperature until
the LC/MS analysis showed the completion of the reaction (typically
30 min–1 hr). Water was added to the reaction mixture and the solid obtained
was filtered off, washed thoroughly with water followed by hexanes, and finally
dried under high vacuum. This intermediate, 2-arylidene-1,3-indandione, was
used in the next step without any further purification.
2-Arylidene-1,3-indandione (1.0 equivalent), 2-aminothiophenol (2.5 equiva-
lent), and anhydrous ZnCl2 (2.0 equivalent) in anhydrous THF (12 ml) were
mixed in a Smith process 20 ml vial and sealed. The reaction mixture was
heated in a microwave reactor at 100C for 1 hr. The mixture was diluted
with CH2Cl2, washed initially with 1 M aqueous HCl and then with saturated
aqueous NaHCO3, and dried over Na2SO4. The solvent was removed in vacuo
and the crude product was purified using an ISCO column (0%–5% MeOH/
CH2Cl2) followed by recrystallization from either acetone/hexanes or CH2Cl2/
hexanes providing benzothiazepines as red or orange solids. Detailed exper-
imental details are provided in the Supplemental Information.ACCESSION NUMBERS
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